Navigation Links
Nephros Reports First Quarter 2012 Financial Results
Date:5/15/2012

three months ended March 31, 2012 were approximately $867,000 compared with approximately $845,000 in the corresponding period of 2011.  The increase was primary due to an increase in research and development expenses of approximately $47,000 or 51% in the first quarter of 2012 compared to the same period in 2011.  Selling, general and administrative expenses in the first quarter of 2012 were materially unchanged.

Nephros' net loss was approximately $557,000 or $0.05 per basic and diluted common share for the first quarter of 2012 versus a net loss of approximately $707,000 or $0.18 per basic and diluted common share in the first quarter of 2011.  At March 31, 2012, Nephros had approximately $2.2 million of cash and cash equivalents.

Europe MD RevenueUnder the licensing agreement with Bellco, S.r.l., Nephros began 2012 with receipt of the second installment payment of EUR 750,000 in January.  The third and final installment payment of euro 600,000 is payable to Nephros on January 15, 2013.  Beginning on January 1, 2015, Nephros will receive royalty payments from Bellco as part of the license agreement.  During the license period, Nephros no longer recognizes MD product sales from the licensed territory, but rather licensing revenue and royalty payments.

U.S. HemodiafiltrationIn April 2012, Nephros received FDA 510(k) clearance to market the Company's hemodiafiltration (HDF) system for the treatment of patients with chronic renal failure when used with a UF controlled hemodialysis machine that provides ultrapure dialysate in accordance with current AAMI/ANSI/ISO standards in the United States.  The Nephros HDF system is the only on-line HDF therapy available in the U.S.  Nephros intends to pursue a limited launch of its HDF system before expanding into the broader market.  In parallel, Nephros intends to explore opportunities to leverage the resources of a strategic partner to most
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
2. Nephros Reports 2009 Third Quarter Financial Results
3. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
4. Nephros Signs Development Agreement with STERIS
5. Nephros Reports 2010 First Quarter Financial Results
6. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
7. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
8. Nephros Reports 2010 Second Quarter Financial Results
9. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
10. Nephros Reports 2010 Third Quarter Financial Results
11. Nephros Rights Offering Registration Statement Declared Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... to release its second quarter 2011 financial results on Tuesday, ... financial markets.  The Company will also host a conference call ... 2011 to discuss its financial results and provide an update ...
... CHADDS FORD, Pa., June 30, 2011 Endo Pharmaceuticals (Nasdaq: ... phase 2 study comparing the novel investigational drug axomadol against ... chronic low back pain. The results indicate that axomadol did ... completing additional analyses of the data and evaluating the path ...
Cached Medicine Technology:Watson to Host Conference Call and Webcast to Discuss Second Quarter 2011 Earnings 2Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain 2
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2
... who eat fish or seafood at least once a week have ... studied a group of 1205 people aged over 65 //and without ... consuming meat, fish and seafood, then followed them up to, five ... seafood at least once a week had a significantly lower risk ...
... the latest study done by the researchers of University of ... the cause if you have abdominal pain, gas and diarrhea.// ... and diarrhea and no obvious reason can be found. They ... with these symptoms may be unable to digest fructose. ...
... study it is indicative that systolic blood pressure is ... with impaired consciousness. This means doctors may now have ... using expensive and time-consuming imaging technology. ,Researchers studied ... to an emergency room with impaired consciousness. Of the ...
... University observed that anomalies in the part of the brain ... Recent studies have linked facial// recognition to a part of ... both the left and right sides of the brain. This ... seeing and also what they may be thinking or feeling ...
... for early outset glaucoma appears to slow the advancement of ... form of glaucoma appears to impact the progression of vision ... to detect it only in a detailed eye exam. In ... glaucoma in one eye. Around half of the group was ...
... to a new study it is observed that reducing blood ... half. It is already known that hypertension (high blood pressure) ... a study carried out by doctors in Dallas, the effect ... ,A group of patients with systolic hypertension - ...
Cached Medicine News:
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles...
BioVintages Biotin-Trapper™ Streptavidin Magnetic Beads (1 mm - 2 mm) are designed for single-step capture of biotinylated molecules such as DNA, RNA or protein from cell lysates or hybridizatio...
... is a method for isolating antibodies, ... cells using affinity binding, while retaining ... on the particles to separate biotinylated ... the MagnaBind™ Beads from the suspension, ...
... m Dynabeads with covalently bound ... any biotinylated target. The Dynabeads® ... area, high capacity, magnetic pull ... during incubation. The MyOne™ products ...
Medicine Products: